Cited by 637Pain Management and Placebo EffectPain Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses

Scott, David J., Stohler, Christian S., Egnatuk, Christine M., Wang, Heng, Koeppe, Robert A., Zubieta, Jon-Kar·2008·Archives of General Psychiatry

Abstract

CONTEXT: Placebo and nocebo effects, the therapeutic and adverse effects, respectively, of inert substances or sham procedures, represent serious confounds in the evaluation of therapeutic interventions. They are also an example of cognitive processes, particularly expectations, capable of influencing physiology. OBJECTIVE: To examine the contribution of 2 different neurotransmitters, the endogenous opioid and the dopaminergic (DA) systems, to the development of placebo and nocebo effects. DESIGN AND SETTING: Using a within-subject design, subjects twice underwent a 20-minute standardized pain challenge, in the absence and presence of a placebo with expected analgesic properties. Studies were conducted in a university hospital setting. PARTICIPANTS: Twenty healthy men and women aged 20 to 30 years recruited by advertisement. MAIN OUTCOME MEASURES: Activation of DA and opioid neurotransmission by a pain stressor with and without placebo (changes in the binding potential of carbon 11 [11C]-labeled raclopride and [11C] carfentanil with positron emission tomography) and ratings of pain, affective state, and anticipation and perception of analgesia. RESULTS: Placebo-induced activation of opioid neurotransmission was detected in the anterior cingulate, orbitofrontal and insular cortices, nucleus accumbens, amygdala, and periaqueductal gray matter. Dopaminergic activation was observed in the ventral basal ganglia, including the nucleus accumbens. Regional DA and opioid activity were associated with the anticipated and subjectively perceived effectiveness of the placebo and reductions in continuous pain ratings. High placebo responses were associated with greater DA and opioid activity in the nucleus accumbens. Nocebo responses were associated with a deactivation of DA and opioid release. Nucleus accumbens DA release accounted for 25% of the variance in placebo analgesic effects. CONCLUSIONS: Placebo and nocebo effects are associated with opposite responses of DA and endogenous opioid neurotransmission in a distributed network of regions. The brain areas involved in these phenomena form part of the circuit typically implicated in reward responses and motivated behavior.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2007.34

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Placebo responses are associated with the release of dopamine and endogenous opioids, whereas nocebo responses are associated with the release of cholecystokinin.

    “Placebo and nocebo responses are also associated with different neurotransmitters; placebo responses are associated with the release of dopamine and endogenous opioids, whereas nocebo responses are associated with the release of cholecystokinin32–34.”

    From Boundary effects of expectation in human pain perception (2019) · cites this paper as [32]

  • Mesolimbic dopamine projections from VTA to NAc are important in analgesic effects induced by placebo and stress, pain relief, and changes in motivated behavior caused by chronic pain.

    “mesolimbic dopamine projections from the ventral tegmental area (VTA) to the NAc are important in the analgesic effects induced by placebo and stress [55],[82], pain relief [58],[83], and the changes in motivated behavior caused by chronic pain [84].”
  • Analgesic placebo effects are mediated by the co-activation of DA and opioid neurotransmission in the ventral striatum (including the nucleus accumbens).

    “Furthermore, analgesic placebo effects are mediated by the co-activation of DA and opioid neurotransmission in the ventral striatum (including the nucleus accumbens) (63), highlighting the potential interactions between DA and EO in the mesolimbic reward circuitry.”

    From Neuroendocrinology of Parental Response to Baby‐Cry (2011) · cites this paper as [63]

  • Using PET techniques, μ-opioid neurotransmission induced by analgesic cognitive expectations, known as placebo effects, are enhanced in the orbital frontal cortex, dorsal and rostral anterior cingulate cortex, nucleus accumbens and midbrain.

    “Using PET techniques, μ-opioid neurotransmission induced by the analgesic cognitive expectations, known as placebo effects, are enhanced in the orbital frontal cortex, dorsal and rostral anterior cingulate cortex, nucleus accumbems and midbrain (63,64).”

    From Neuroendocrinology of Parental Response to Baby‐Cry (2011) · cites this paper as [63]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K.
Affiliations
  • University of Michigan (US)
  • University of Maryland, Baltimore (US)
Venue
Archives of General Psychiatry
Published
2008-02-01
Volume
65
Issue
2
Pages
220
ISSN
0003-990X (ISSN-L)
OpenAlex
W2013302461
Cited by
637
References
16
Citations by year
2026: 12 · 2025: 18 · 2024: 29 · 2023: 22 · 2022: 24 · 2021: 31 · 2020: 38 · 2019: 39 · 2018: 39 · 2017: 46 · 2016: 41 · 2015: 52 · 2014: 46 · 2013: 43 · 2012: 35
FWCI
20.07
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of General Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Drug Abuse (R01DA016423)
  • National Center for Complementary and Alternative Medicine
  • National Institute of Dental and Craniofacial Research (R01DE015396)
  • National Center for Complementary and Integrative Health (R01AT001415)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
placebo effect, nocebo effect, endogenous opioids, dopaminergic system, nucleus accumbens, placebo analgesia, pain anticipation, reward systems, [11C]raclopride, [11C]carfentanil, positron emission tomography
MeSH terms
Adult, Analgesics, Brain, Brain Mapping, Carbon Radioisotopes, Culture, Female, Fentanyl, Humans, Image Processing, Computer-Assisted, Male, Synaptic Transmission, Pain, Pain Measurement, Receptors, Dopamine, Receptors, Opioid, Placebo Effect, Receptors, Dopamine D2, Receptors, Opioid, mu, Raclopride, Positron-Emission Tomography, Receptors, Dopamine D3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review